Dendritic Cell Vaccines Against Non‑ small Cell Lung Cancer – an Emerging Therapeutic Alternative

Česká verzia

Authors: L. Mendoza
Authors place of work: INC Research, Prague, Czech Republic
Published in the journal: Klin Onkol 2014; 27(4): 294-298
Category: Short Communication

Summary

Many clinical trials have been carried out or are in progress to assess the therapeutic potential of dendritic cell-based vaccines on cancer patients. Herewith, we describe the clinical trials of non‑small cell lung cancer (NSCLC) published in the literature. Although the number of clinical trials and NSCLC patients enrolled in these studies is small, it is possible to conclude that the administration of dendritic cells (DCs) by any route is safe and that a clinical benefit after their administration can be observed. These initial results encourage continued investigation in clinical trials into the benefit of DCs along with different strategies to enhance their immune response in this deadly disease.

Key words:
dendritic cells – non-small cell lung cancer – cancer – immunotherapy

The author declare he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
15. 3. 2014

Přijato:
7. 6. 2014

Zdroje

1. O‘Mahony D, Kummar S, Gutierrez ME. Non‑ small‑cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005; 23(35): 9022– 9028.

2. Molina JR, Yang P, Cassivi SD et al. Non‑ small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 2008; 83(5): 584– 594. doi: 10.4065/ 83.5.584.

3. Baleeiro RB, Anselmo LB, Soares FA et al. High frequency of immature dendritic cells and altered in situ production of interleukin‑4 and tumor necrosis factor‑alpha in lung cancer. Cancer Immunol Immunother 2008; 57(9): 1335– 1345. doi: 10.1007/ s00262‑ 008‑ 0468‑ 7.

4. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995; 16(1): 2– 4.

5. Peters JH, Gieseler R, Thiele B et al. Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol Today 1996; 17(6): 273– 278.

6. Knight SC, Hunt R, Dore C et al. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985; 82(13): 4495– 4497.

7. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex‑ restricted antitumor immunity. J Exp Med 1996; 183(1): 7– 11.

8. Paglia P, Chiodoni C, Rodolfo M et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183(1): 317– 322.

9. Zou JP, Shimizu J, Ikegame K et al. Tumor‑ immunotherapy with the use of tumor‑ antigen‑ pulsed antigen‑ presenting cells. Cancer Immunol Immunother 1992; 35(1): 1– 6.

10. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti‑tumor immunity. Nat Med 1995; 1(12): 1297– 1302.

11. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide‑ pulsed dendritic cells induce antigen‑ specific, CTL‑ mediated protective tumor immunity. J Exp Med 1996; 183(1): 283– 287.

12. Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)– A3 expression in stages I and IInon‑small cell lung cancer: results of a multi‑center study. Eur J Cardiothorac Surg 2004; 25(1): 131– 134.

13. Reck M, Vansteenkiste J, Brahmer JR. Targeting the immune system for management of NSCLC: the revival? Curr Respir Care Rep 2013; 2(1): 22– 39. doi: 10.1007/ s13665‑ 012‑ 0038‑ 5.

14. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non‑small‑cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23(14): 3227– 3234.

15. Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 2010; 40(5): 377– 387. doi: 10.1093/ jjco/ hyp194.

16. Coligan JE, Henkart PA, Todd CW et al. Heterogeneity of the carcinoembryonic antigen. Immunochemistry 1973; 10(9): 591– 599.

17. Babiak A, Steinhauser M, Götz M et al. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. J Oncol Rep 2014; 31(1): 384– 390. doi: 10.3892/ or.2013.2804.

18. Butterfield LH. Dendritic cells in cancer immunotherapy clinical trials: Are we making progress? Front Immunol 2013; 4: 454. doi: 10.3389/ fimmu.2013.00454.

19. Edward A. Hirschowitz, Terry Foody et al. Autologous dendritic cell vaccines for non‑small‑cell lung cancer. J Clin Oncol 2004; 22(14): 2808– 2815.

20. Hirschowitz EA, Foody T et al. Immunization of NSCLC patients with antigen‑ pulsed immature autologous dendritic cells. Lung Cancer 2007; 57(3): 365– 372.

21. Kimura H, Iizasa T, Ishikawa A et al. Prospective phase II study of post‑surgical adjuvant chemo‑ immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor‑ draining lymph nodes in primary lung cancer patients. Anticancer Res 2008; 28(2B): 1229– 1238.

22. Perroud MW Jr, Honma HN, Barbeiro AS et al. Mature autologous dendritic cell vaccines in advanced non‑small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res 2011; 30: 65. doi: 10.1186/ 1756‑ 9966‑ 30‑ 65.

23. Noerregaard L, Kvistborg P, Zocca M et al. Clinical and immunological effects in patients with advanced non‑small cell lung‑ cancer after vaccination with dendritic cells exposed to an allogeneic tumor cell lysate. W J V 2013; 3(2): 68– 76. doi: 10.4236/ wjv.2013.32011.

24. Takahashi H, Okamoto M, Shimodaira S et al. Impact of dendritic cell vaccines pulsed with Wilms’ tumour‑ 1peptide antigen on the survival of patients with advanced non‑small cell lung cancers. Eur J Cancer 2013; 49(4): 852– 859. doi: 10.1016/ j.ejca.2012.11.005.

25. Tuyaerts S, Aerts J, Corthals J et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56(10): 1513– 1537.

26. Kandalaft LE, Chiang Ch, Tanyi J et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med 2013; 11: 149. doi: 10.1186/ 1479‑ 5876‑ 11‑ 149.